Market Overview

UPDATE: BMO Capital Markets Reiterates Market Perform Rating, Raises PT on Eli Lilly & Co.

Share:
Related LLY
Eli Lilly Shares Go Parabolic
Sales Of This Eli Lilly Drug Could Nearly Double Wall St. Consensus In 2020, SunTrust Predicts
The Blockbuster Drug Cyramza May Not Be The Savior Eli Lilly Was Hoping For (Seeking Alpha)

In a report published Monday, BMO Capital Markets reiterated its Market Perform rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $47.00 to $52.00.

BMO Capital Markets noted, “Eli Lilly provided financial guidance for 2013 and reconfirmed its mid-term guidance through 2014. The company reiterated its expectation to reach 2014 revenues of at least $20Bn and net income of at least $3Bn (consensus was $19.6Bn and $2.9Bn, respectively, on January 4, 2013). In 4Q12, Lilly repurchased roughly 16.9MM ($819MM) shares and plans to complete the remaining $1.1Bn of its share buyback program in 2013.”

Eli Lilly & Co. closed on Friday at $51.56.

Latest Ratings for LLY

DateFirmActionFromTo
Jun 2015Leerink SwannMaintainsOutperform
Jun 2015Bank of AmericaUpgradesNeutralBuy
Jun 2015Argus ResearchMaintainsBuy

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

Around the Web, We're Loving...

Get Benzinga's Newsletters